Clover Health Investments, Corp. (CLOV) Stock Price & Analysis
Clover Health Investments, Corp. (CLOV) closed at USD 4.73 on Thursday, October 22, 2026, down 1.05% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 4.78; the Oct 22, 2026 session ranged USD 4.64–4.8 on volume of 3,189,699 shares. Market capitalization is $2.51B, with a 52-week range of USD 1.58–5.59 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:06 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CLOV.md
Key facts (CLOV)
- Last four reported quarters (through Jun 30, 2026): revenue $2.48B, net income -$18.4M (-0.7% margin), free cash flow $74.2M (SEC filings).
- Analysts: Hold (mean 2.50 on a 1–5 scale) (4 analysts), mean target USD 5.38 (range 5–6).
- Total return with dividends: 1Y +47.8% vs S&P 500 +14.9%; 5Y -36.9% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 0.01, revenue estimate $738M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CLOV)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.47B | $1.10B | $1.26B | $1.37B | $1.92B | $2.48B |
| Gross profit | -$79.2M | $22.7M | $257M | — | — | — |
| Operating income | -$637M | -$287M | -$205M | -$45.7M | -$85.5M | -$18.4M |
| Net income | -$588M | -$340M | -$213M | -$43.0M | -$85.5M | -$18.4M |
| EPS (diluted) | -$1.42 | -$0.71 | -$0.44 | — | — | — |
| Free cash flow | -$283M | -$208M | -$145M | $33.3M | -$69.0M | $74.2M |
| Gross margin | -5.4% | 2.1% | 20.4% | — | — | — |
| Operating margin | -43.3% | -26.1% | -16.3% | -3.3% | -4.4% | -0.7% |
| Net margin | -39.9% | -31.0% | -16.9% | -3.1% | -4.4% | -0.7% |
| Revenue growth | +118.8% | -25.5% | +15.0% | +8.8% | +40.3% | — |
| Cash + short-term investments | $321M | $293M | $224M | $222M | $101M | — |
| Total debt | $20.0M | $0K | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CLOV)
P/S 1.0x · P/FCF 33.9x · P/B 6.7x · FCF yield 2.95% · Earnings yield -0.73% · Buyback yield (TTM) 0.00%
Analysts (CLOV)
Consensus Hold (mean 2.50 on a 1–5 scale), 4 analysts; mean target USD 5.38 (low 5, high 6).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-06 | UBS | Target raised | Neutral | $4.75 → $5 |
| 2026-07-21 | Canaccord Genuity | Target raised | Buy | $4.2 → $5.5 |
Total return (dividends reinvested) (CLOV)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +47.8% | -36.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +48.0% | -8.8% |
| Volatility (annualized) | 63.9% | 74.4% |
| Max drawdown | -55.5% (Oct 2025→Apr 2026) | -91.9% (Nov 2021→Apr 2024) |
CLOV suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Amazon (AMZN) | “We rely on cloud service providers, such as Amazon Web Services and Google Cloud, to provide the cloud computing infrastructure that we use to host our platform, products, and many of the internal tools we use to operate our business.” |
| Supplier | Alphabet (Google) (GOOGL) | “We rely on cloud service providers, such as Amazon Web Services and Google Cloud, to provide the cloud computing infrastructure that we use to host our platform, products, and many of the internal tools we use to operate our business.” |
| Customer | Counterpart Health | “While we believe that our risk adjustment data collection efforts and relationships with providers, including those related to Clover Assistant, comply with applicable laws, we and our Counterpart Health customers are and may be subject to audits, reviews and investigation of our practices and arrangements, and the federal government might conclude that they violate the FCA, the Anti-Kickback Statute and/or other …” |
Quoted from the company's 10-K filed Feb 27, 2026.
CLOV analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.01 | $0.00 | — | $738.2M | 1 |
| Next quarter (ends Dec 2026) | $-0.02 | $-0.04 | -50.0% | $723.5M | 1 |
| Current fiscal year (ends Dec 2026) | $0.14 | $0.09 | +55.6% | $2.95B | 1 |
| Next fiscal year (ends Dec 2027) | $0.15 | $0.10 | +50.0% | $3.53B | 1 |
CLOV options: expected move
Options price a move of about ±12.1% (±$0.57) by Nov 6, 2026, which includes earnings on Nov 4, 2026; the earnings reaction alone is priced at about ±7.7%. Over the last 8 reports the stock moved ±10.5% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 54.8% | ±7.6% |
| Nov 6, 2026 | 14 | 71.5% | ±12.1% |
| Nov 13, 2026 | 21 | 78.4% | ±15.6% |
| Nov 20, 2026 | 28 | 73.1% | ±16.7% |
| Nov 27, 2026 | 35 | 73.6% | ±18.6% |
| Dec 4, 2026 | 42 | 73.6% | ±20.2% |
| Dec 18, 2026 | 56 | 60.9% | ±19.5% |
| Jan 15, 2027 | 84 | 60.7% | ±23.2% |
30-day implied volatility 70% vs 53.5% realized over the last 30 trading days. Put/call ratio (volume) 0.79. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 10:06 UTC)
| Price | USD 4.73 |
|---|---|
| Change | ▼ 1.05% (down) |
| Previous Close | USD 4.78 |
| Open | USD 4.77 |
| Day Range | USD 4.64 – 4.8 |
| 52-Week Range | USD 1.58 – 5.59 |
| Volume | 3,189,699 shares |
| Market Cap | $2.51B |
| Exchange | NMS |
Technical Analysis (CLOV)
Nexqual's technical model rates CLOV "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 10:06 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.56 (neutral) |
| vs SMA50 | Above (USD 4.47) |
| MACD | 0.06 (positive) |
Analyst Ratings (CLOV)
Wall Street analysts rate CLOV "Hold" based on 4 analysts, with a mean price target of USD 5.38 (range USD 5–6), per Nexqual as of October 23, 2026 at 10:06 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 5.38 |
| High Target | USD 6 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 2 / 2 / 0 |
Earnings (CLOV)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.01 |
| Revenue Estimate | $738.18M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.07 vs est 0.05 ▲ beat |
| 2026-03-31 | USD 0.07 vs est 0.07 ▲ beat |
| 2025-12-31 | USD -0.05 vs est -0.05 ▲ beat |
| 2025-09-30 | USD 0 vs est 0.02 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:06 UTC.
Financials & Fundamentals (CLOV)
| Total Revenue | $2.48B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +55.60% |
| Gross Margin | +18.54% |
| Operating Margin | +3.77% |
| Profit Margin | -0.74% |
| ROE | -5.10% |
| Current Ratio | 1.5 |
| Total Cash | $243.10M |
| Total Debt | $0 |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $74.21M (3.0% of revenue) |
Source: Nexqual, October 23, 2026 at 10:06 UTC.
Financial Health Score (CLOV)
Nexqual rates Clover Health Investments, Corp.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:06 UTC.
| Growth | Strong — Revenue +40% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 19%, operating 4% (last 12 months) |
| Balance Sheet | Mixed — $243M cash, no debt |
| Cash Flow | Mixed — FCF $74M (last 4 quarters to Jun 2026, SEC), slim 3.0% margin |
| Efficiency | Critical — ROE -5%, ROA -1.8% |
Ownership (CLOV)
| Insider Ownership | +4.19% |
|---|---|
| Institutional Ownership | +33.95% |
| Shares Outstanding | 435.44M |
| Float | 412.67M |
| Short % of Float | +5.45% |
Source: Nexqual, October 23, 2026 at 10:06 UTC.
Leadership (CLOV)
Clover Health Investments, Corp. is led by Andrew Toy, Co-Founder, CEO & Director, per Nexqual as of October 23, 2026 at 10:06 UTC.
| Co-Founder, CEO & Director | Andrew Toy |
|---|---|
| Co-Founder & Executive Chairman | Vivek Garipalli |
| Interim Chief Financial Officer | Clay Thornton |
Major Backers & Investors (CLOV)
Notable institutional backers of Clover Health Investments, Corp. include Fidelity, Charles Schwab Investment Management, Inc., PNC Financial Services Group, Inc., according to Nexqual as of October 23, 2026 at 10:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.52% |
| Charles Schwab Investment Management, Inc. | 1.27% |
| PNC Financial Services Group, Inc. | 0.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.06% |
| Vanguard Group | 5.17% |
| Geode Capital | 2.49% |
| State Street | 2.34% |
| Nuveen | 1.44% |
| Northern Trust | 0.87% |
Source: Nexqual, October 23, 2026 at 10:06 UTC.
From Clover Health Investments, Corp.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- We have made significant investments into extending our proprietary technology platform, enabling Clover Assistant functionality to be embedded quickly and seamlessly into major EHR systems, including Epic, Cerner, Athena and others.
- During 2024, the Company launched Counterpart Health, Inc., a new Software-as-a-Service ("SaaS") and Tech Enabled Services Solution to bring the power of Clover Assistant technology to external payors and providers serving the Medicare eligible population.
- Our proprietary technology platform is at the center of the Company's technology-first approach to driving better care management.
- Clover Assistant identifies opportunities for improvement in clinical quality gaps, including those prioritized by Centers for Medicare & Medicaid Services' ("CMS") Star Ratings Program (plan performance measures that drive bonus payments for plan providers), such as prescription drug adherence, regular cancer screenings and the annual flu shot.
Legal & Regulatory Risks (Item 1A, quoted)
- Failure to maintain satisfactory quality and service measures could also adversely affect our ability to establish new health plans or expand the business of our existing health plans.
- Our business activities are highly regulated, and new and proposed government regulation or legislative reforms could increase our cost of doing business and reduce our number of members, profitability, and liquidity.
- Our use and disclosure of personally identifiable information, including health information, is subject to federal and state privacy and security regulations. Our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our client base and results of operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PGNY | Progyny, Inc. | USD 29.12 | ▲ 2.39% |
| ALHC | Alignment Healthcare, Inc. | USD 8.43 | ▼ 0.12% |
| OSCR | Oscar Health, Inc. | USD 33.32 | ▼ 0.39% |
| MOH | Molina Healthcare Inc | USD 216.64 | ▲ 0.81% |
| CNC | Centene Corporation | USD 71.24 | ▲ 1.42% |
| HUM | Humana Inc. | USD 420.97 | ▼ 1.05% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:06 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt